Prof. Tamara Lah Turnšek
was born in Ljubljana, Slovenia. She holds a BS in Organic Chemistry, a PhD in Biochemistry, both from the University of Ljubljana. Lah has been the Director of National Institute of Biology in Ljubljana since 1996, leading the 3rd largest public research institution for natural sciences in Slovenia till March 2018. She established the Department of Genetic Toxicology and Cancer Biology and is the Programme leader of this research group. Since 2004 she is also Professor at the Biotechnical Faculty of the University of Ljubljana, teaching Cancer Biology, as well as Stem cells and Proteases at the Josef Stefan Postgraduate School. Basic research interests of Prof. Lah comprise the role of proteolytic enzymes and their inhibitors in pathophysiological conditions, particularly in cancer. Recently, her research has focused on brain tumours - glioma and the role of normal stem cells in tumour progression and therapy (www.nib.si.tamara
Tamara Lah started and developed her scientific career at the Department of Biochemistry and Molecular Biology of the Jožef Stefan Institute in Ljubljana. Her professional career outside Slovenia includes the positions of Visiting Research Assistant at University of Bonn, Germany, and Visiting Research Associate at the University of Newcastle upon Tyne, UK, where she performed part of her PhD research in the field of protein biochemistry. She gained her postdoctoral experiences at the Department of Pharmacology, School of Medicine, Wayne State University, Detroit, Michigan, USA, where she became Assistant Professor (1984-1987). From 1991 to 1994 she was Visiting Professor and Director of Metastasis Research Laboratory at Albert Einstein Medical Centre, Philadelphia, Pennsylvania, USA.
As Director of the National Institute of Biology for twenty consecutive years Tamara Lah actively participates in national and international science policy. At present she is President of the Science and Technology Council of the Government of Slovenia. Prior to that (1993-1994) she was appointed as the Counsellor for Medical Sciences at the Ministry of Science and Technology of Slovenia. Between 2000 and 2008 she was President of the National Committee for Equal Opportunity for Women Scientists, and an active member of the EU Helsinki group “Women in Science”. In 2013 she was nominated by the Government of Slovenia to be the President of the Committee for National Science ZOIS Awards.
Research - major achievements in the field
Basic research interests of Prof. Tamara Lah Turnšek comprise the role of proteases and their inhibitors in physiological and pathological conditions, particularly in cancer, such as breast, lung and brain tumours, especially glioma. Her work on the use of proteases is applicable in clinical practice, both in diagnostics and in therapy as biomarkers. Lah Turnšek collaborated with Krka company in the production of diagnostic immunoassays. She is an elected member of the Pathobiology group of the European Organisation of Research and Treatment of Cancer (EORTC). In carcinogenesis research, her group recently published on the interesting mechanisms of arsenite (Trisenox) treatment of glioblastoma. This work a focused on the possible use of selective cathepsin inhibitors in combination with chemo therapeutics (Primon et al., 2017). Aside from that, her research team has focused on the chemop-preventive, as well as cytotoxic effects of natural substances, such as flavonoids, xanthohumol (Zajc et al., 2012), resveratrol (Castino et al., 2011) and in collboartion with Brazilian group of Prof. Maria Luiza Oliva, also on tropic plant extracts Enterolobium contortisiliquum Trypsin Inhibitor (EcTI)v (Bouturi et al., 2018).
Glioblastoma (GBM ( the most malignant brain tumour ) has been the focus of the Lah’s team research. She is involved in long-term collaboration with the Department of Neurosurgery of the University Medical Centres in Ljubljana and in Maribor, performing pre-clinical studies in finding novel biomarkers allowing early prognosis and testing the response to therapy in vitro. Studying the processes such as autophagy and apoptosis in tumour cells, novel aspects of the role of proteases were revealed (Pucer et al, 2010; Kenig et al., 2011). Last few years the pre-clinical research of the groups focuses on GBM stem cell. Her group was the first to find that the novel stem cell marker, tetraspanin CD9 is a highly selective GSC marker in contrast to the markers currently used; This membrane protein (CD9) may also prove to be a good therapeutic target for eradication of resistant GSC (Podergajs et al., 2016).
Next important major research topic of the Prof. Lah’s group is tumour microenvironment that significantly contributes to cancer progression. Her recent research is focused on the cross–communication between tumour and stromal cells, for example with normal tissue mesenchymal stem cells, infiltrating the tumour. Recently she has been involved mostly in studying cellular interactions of cancer associated with stem cells at the level of transcriptomics and proteomics, using systems biology approaches. The potential application of mesenchymal stem cells is currently being investigated, showing that their effects on tumour tissue are highly dependent on intra-tumour heterogeneity (Breznik et al., 2017; Neves-Oliveira et al., 2017). This research is leading to identification of the GBM stem cells niche, where the most resistant tumour cells are “hiding” from therapeutics’ effects (Hira et al., 2017). Latest studies revealed a very complex interplay between glioma autonomous and non-autonomous environment. A 3-dimensional spheroid model comprised of multiple types of is being developed in the laboratory to be used as a better model mimicking microenvironment for testing drugs, in collaboration with industrial partners, such as company Novartis-Lek d.o.o in Slovenia.
- BS Engineer (1971), Chemistry, Faculty of Natural Sciences and Technology, University of Ljubljana (UL), Slovenia
- Msci (1974), Biochemistry, UL
- PhD (1981), Biochemistry, UL (in collaboration with Newcastle University, Newcastle upon Tyne, UK).
Positions and employment
- 1918-present. Counselor to the director and Scientific Councilor
- 1996–2018: Director of the Institute and Scientific Councilor, Programme Leader
National Institute of Biology (NIB), Ljubljana, Slovenia
- 2004-present: Professor of Biochemistry and Molecular Biology (part time employment)
Dept. of Biochemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana (UL), Ljubljana, Slovenia
- 1996-2002: Assistant Professor
Biotechnical Faculty, UL
- 1994-1996: Head of the Department of Genetic Toxicology and Cancer Biology
- 1991-1994: Director of Metastasis Research
Albert Einstein Medical Center, 5505 Old York Road, Philadelphia, Pennsylvania, USA
- 1988-1991: Research Associate – Assistant Professor
Dept. of Biochemistry and Molecular Biology, Jožef Stefan Institute (IJS), Ljubljana, Slovenia
- 1984-1987: Senior Research Associate, Visiting Assistant Professor (since 1986)
Medical Faculty, Wayne State University Detroit, Michigan, USA
- 1979-1985: Research Associate
Dept. of Biochemistry and Molecular Biology, IJS
- 1974-1979: Research Assistant
Clinical Laboratory, Paediatric Clinic, University Medical Centre, Ljubljana, Slovenia
- 1971-1974: Research Associate
Dept. of Biochemistry and Molecular Biology, IJS
Research Projects (last 5 years)
- ARRS Programme P1-0245: Ecotoxicology, toxicogenomics and carcinogenesis (2000-2005, 2015-2019)
- ARRS J1-0295: Apoptosis of tumour cells as therapeutic target (2009-2012)
- ARRS J1 6373: Dual role of stem cells in cancer progression (2011-2014)
- ARRS J1-71119: Biology at Structural Level of EpCAM as a Foundation for Efficient Tumor Targeting (PI B. Lenarčič, FKKT; Co-PI T.Lah, 2016-2018)
Major International Projects:
ERA-NET Virtual Institute (PathoGenoMics) INREMOS: SYSTHER- Systems Biology Tools Development for Cell Therapy and Drug Development (2006-2011) formed a partnership between Slovenian teams from NIB and the Blood Transfusion Centre and German groups from the University of Postdam/Institute of Biochemistry and Biology/Max Planck Institute of Molecular Plant Physiology, Junior Research Group Systems Immunology/Institute for Theoretical Biology, Humboldt-University Berlin, University Clinic for Neurosurgery/Ludwig-Maximilian-University of Munich (LMU) in Großhadern and MicroDiscovery GmbH. The total value of the project was 5 M EUR.
GLIOMA - Determination of New Biomarkers of Brain Tumours as Diagnostic indicators and Therapeutic Targets in the scope of the European Cross-Border Cooperation Programme Italy-Slovenia (2008-2015). GLIOMA was a three-year project with a total value of 1.3 M EUR. Apart from NIB, the Medical Faculty, University of Ljubljana, University Medical Centre Ljubljana (Department of Neurosurgery) collaborated on the Slovenian side and the University Hospital in Udine and Sinchrotrone Trieste were project partners from Italy.
TRANSGLIOMA, Interreg SLO-IT Programme: New Therapies of glioblastoma based on cross-border translation research platform (2017-2020), (Coordinator for NIB T. Lah), is the continuation of GLIOMA, the financing of was approved in July 2017 and will be performed by the same group of scientists and clinicians. It is intended to validate the GSC markers newly discovered in the scope of the GLIOMA project, they will now be validated by animal testing and in clinical settings.
The Relevance of Kinin and Related Purinergic Signalling Pathways in Gliobastoma Cells upon Co-culturing with Human Mesenchymal Stem Cells Research in cooperation with the Brazilian National Council of Technological and Scientific Development (CNPq) - Project Linha 2 (Bolsa Pesquisador Visitante Especial Edital Nº 61/20119) hosted by Co-PI Prof. Henning Ulrich at the University of Sao Paolo, Institute of Chemistry.
Organization of scientific and professional meetings:
- EIGHT consecutive organizations of the International Conferences on Experimental and Translational Oncology - CETO in Kranjska Gora and Portorož in the Spring of 2000, 2002, 2004, 2006 and 2008, 2011, 2013 and 2017 which was under the chairmanship of Tamara Lah, related research and treatment of cancer. The useful, or socio-economic significance of the conference, is that it accelerates the transition between laboratory research and the patient's bed.
- Participation and organization of two meetings of the Glioma Invasion Forum (Portorož-MBP 2009 and 2017).
Prof. Lah received her academic title Professor of biochemistry and molecular biology at the Biotechnical Faculty, UL, and teaches in Bologna II stage programmes at:
- Department of Biology, BF, UL: Biology of Cancer
- Chair of Biochemistry, FKKT, UL: Tumour Biochemistry
- Biomedicine, Medical Faculty, UL: Molecular mechanisms in ignition and development of cancer (co-lecturing)
- International postgraduate school (IPS) Josef Stefan,
- Programme Nanoscience and nanotechnologies: Proteolytic systems in cancer and
- Programme Sensor technologies: Synthetic biology and biosensors
Prof. Lah was invited as “Honorary invited lecturer SPINOZA” to the University Amsterdam Academic Medical Centre in June 2011. She was teaching medical doctoral students and tutoring seminars on stem cells in cancer and the role of proteolytic systems in cancer progression, in particular in brain tumours.
Tamara Lah was appointed as Visiting Professor at University of Sao Paolo between October 2013–2016, holding a course on “Selected themes on tumour biology” for doctoral students of biochemistry at the Instituto de Química. The Programme was sponsored by CNPq, the Brazilian National Council of Technological and Scientific Development and has contributed to academic collaboration between Slovenia and Brasil.
Prof. Lah was supervisor to 14 Doctoral students, 11 Master students and 18 Bachelor students. In 2017/2018 she is supervising three Doctoral students and one (1) student, who is doing a “sandwich PhD” at University of Sao Paolo and IPS.
Recent PhD Theses:
TORKAR, Ana. Development of selective cathepsin L inhibitors (2013).
PODERGAJS, Neža. The role of EGFR and FGRF signal pathways and new biomarkers of glioblastoma stem cells (2013).
PRIMON, Monika. The effects of arsenic trioxide and cathepsin L silencing and mesnechymal stem cells effects on glioblastoma cells (2014).
KOLOŠA, Katja. Optimization of human mesenchymal stem cells production and their mutual interactions with tumour cells (2016).
VERBOVŠEK, Urška. Cathepsin K as potential tumour marker in glioblastoma multiformae (2016).
BURJEK, Mateja. The expression of genes of proteases in mesenchymal stem cell and glioblastoma cell co-cultures (Master Thesis) (2017).
BREZNIK, Barbara. The glioblastoma invasion : proteases, microenvironment and stem cells : doctoral dissertation (2018)
VIDIC Mateja. Development of DNA Aptamers Specific for Non-Small Lung Cancer Adenocarcinoma and Stem Cells Marker (2018)
Membership in scientific societies,
Tamara Lah Turnšek was elected to be the member of the Engineer Society of Slovenia (IAS) in 2015.
She was a member of an EU Advisory Board and Committees in the field of Life sciences and biomedicine (cancer research) and served as evaluator of EU projects and Joint Research Centres.
She is also member of:
- American Association for Cancer Research,
- European Association of Cancer Research,
- European Organisation for Research and Treatment of Cancer: full member of Patho-Biology Group,
- European Association of Neuro-oncolgy,
- International Proteolysis Society,
- Slovenian Biochemical Society,
- Genetic Society Slovenia,
- Slovenian Association of Radiology,
- Slovenian Society of Toxicology
- Cell and Tissue Engineering Society of Slovenia.
Selected recent publications 2010-2018
1. TOMC, Jana, KOLOŠA, Katja, ŽEGURA, Bojana, KAMENŠEK, Urška, BREZNIK, Barbara, LAH TURNŠEK, Tamara, FILIPIČ, Metka. Adipose tissue stem cell-derived hepatic progenies as an in vitro model for genotoxicity testing. Archives of toxicology, ISSN 0340-5761, 2018, 11 str., [in press], doi: 10.1007/s00204-018-2190-3.
2. BONTURI, Camila, MOTALN, Helena, LAH TURNŠEK, Tamara, et al. Could a plant derived protein potentiate the anticancer effects of a stem cell in brain cancer?. Oncotarget, ISSN 1949-2553, 2018, vol. 9, no. 30, str. 21296- 21312, doi: 10.18632/oncotarget.25090.
3. NEVES OLIVEIRA, Mona das, PILLAT, Micheli M., MOTALN, Helena, ULRICH, Henning, LAH TURNŠEK, Tamara. Kinin-B1 receptor stimulation promotes invasion and is involved in cell-cell interaction of co-cultured glioblastoma and mesenchymal stem cells. Scientific reports, ISSN 2045-2322, 2018, vol. 8, str. 1299-1-1299-16, doi: 10.1038/s41598-018-19359-1.
4. HIRA, Vashendriya V. V., VERBOVŠEK, Urška, BREZNIK, Barbara, SRDIČ, Matic, NOVINEC, Marko, KAKAR, Hala, WORMER, Jill, SWAAN, Britt van der, LENARČIČ, Brigita, JULIANO, Luiz, MEHTA, Shwetal, NOORDEN, Cornelis J. F. van, LAH TURNŠEK, Tamara. Cathepsin K cleavage of SDF-1[alpha] inhibits its chemotactic activity towards glioblastoma stem-like cells. Biochimica et biophysica acta. BBA, Molecular cell research, ISSN 0167-4889. [Print ed.], 2017, vol. 1864, no. 3, str. 594-603, doi: 10.1016/j.bbamcr.2016.12.021.
5. PRIMON, Monika, HUSZTHY, Peter C., MOTALN, Helena, TALASILA, Krishna M., MILETIC, Hrvoje, ATAI, Nadia A., BJERKVIG, Rolf, LAH TURNŠEK, Tamara. Cathepsin L silencing increases As2O3 toxicity in malignantly transformed pilocytic astrocytoma MPA58 cells by activating caspases 3/7. Experimental cell research, ISSN 0014-4827, 2017, vol. 356, iss. 1, str. 64-73, doi: 10.1016/j.yexcr.2017.04.013.
6. BREZNIK, Barbara, MOTALN, Helena, LAH TURNŠEK, Tamara. Proteases and cytokines as mediators of interactions between cancer and stromal cells in tumours. Biological chemistry, ISSN 1431-6730, 2017, vol. 398, no. 7, str. 709-719, doi: 10.1515/hsz-2016-0283. [COBISS.SI-ID 4176463], [JCR, SNIP, WoS up to 24. 6. 2017: no. of citations (TC): 0, without self-citations (CI): 0, Scopus up to 29. 5. 2018: no. of citations (TC): 1, pure citations (CI): 1]
7. VERBOVŠEK, Urška, NOORDEN, Cornelis J. F. van, LAH TURNŠEK, Tamara. Complexity of cancer protease biology : cathepsin K expression and function in cancer progression. Seminars in cancer biology, ISSN 1044-579X. [Print ed.], 2015, vol. 35, str. 71-84, doi: 10.1016/j.semcancer.2015.08.010.
8. VITTORI, Miloš, BREZNIK, Barbara, HROVAT, Katja, KENIG, Saša, LAH TURNŠEK, Tamara. RECQ1 helicase silencing decreases the tumour growth rate of U87 glioblastoma cell xenografts in zebrafish embryos. Genes, ISSN 2073-4425, 2017, vol. 8, no. 9, str. 1-11. http://www.mdpi.com/2073-4425/8/9/222, doi: 10.3390/genes8090222.
9. BREZNIK, Barbara, MOTALN, Helena, VITTORI, Miloš, ROTTER, Ana, LAH TURNŠEK, Tamara. Mesenchymal stem cells differentially affect the invasion of distinct glioblastoma cell lines. Oncotarget, ISSN 1949-2553, 2017, vol. 8, no. 15, str. 25482-25499, doi: 10.18632/oncotarget.16041
10. MITROVIĆ, Ana, SOSIČ, Izidor, KOS, Špela, LAMPREHT TRATAR, Urša, BREZNIK, Barbara, KRANJC, Simona, MIRKOVIĆ, Bojana, GOBEC, Stanislav, LAH TURNŠEK, Tamara, ČEMAŽAR, Maja, SERŠA, Gregor, KOS, Janko. Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in vitro and in vivo. Oncotarget, ISSN 1949-2553, 2017, vol. 8,
11. AL-SERORI, Halh, KUNDI, Michael, FERK, Franziska, MIŠÍK, Miroslav, NERSESYAN, Armen, MURBACH, Manuel, LAH TURNŠEK, Tamara, KNASMÜLLER, Siegfried. Evaluation of the potential of mobile phone specific electromagnetic fields (UMTS) to produce micronuclei in human glioblastoma cell lines. Toxicology in vitro, ISSN 0887-2333, 2017, vol. 40, str. 264-271. http://doi.org/10.1016/j.tiv.2017.01.012, doi: 10.1016/j.tiv.2017.01.012.
12. KENIG, Saša, FAORO, Valentina, BOURKOULA, Evgenia, PODERGAJS, Neža, LAH TURNŠEK, Tamara, SKRAP, Miran, et al. Topoisomerase IIB mediates the resistance of glioblastoma stem cells to replication stress-inducing drugs. Cancer cell international, ISSN 1475-2867, July 2016, vol. 16, art. no. 58, str. 1-10, ilustr., doi: 10.1186/s12935-016-0339-9.
13. PODERGAJS, Neža, MOTALN, Helena, RAJČEVIĆ, Uroš, VERBOVŠEK, Urška, KORŠIČ, Marjan, OBAD, Nina, ESPEDAL, Heidi, VITTORI, Miloš, HEROLD-MENDE, Christel, MILETIC, Hrvoje, BJERKVIG, Rolf, LAH TURNŠEK, Tamara. Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells. Oncotarget, ISSN 1949-2553, 2016, vol. 7, no. 1, str. 593-609, ilustr., doi: 10.18632/oncotarget.5477.
14. VEČERIĆ-HALER, Željka, ERMAN, Andreja, CERAR, Anton, MOTALN, Helena, KOLOŠA, Katja, LAH TURNŠEK, Tamara, SODIN-ŠEMRL, Snežna, LAKOTA, Katja, MRAK POLJŠAK, Katjuša, ŠKRAJNAR, Špela, KRANJC, Simona, ARNOL, Miha, PERŠE, Martina. Improved protective effect of umbilical cord stem cell transplantation on cisplatin- induced kidney injury in mice pretreated with antithymocyte globulin. Stem Cells International (Online), ISSN 1687-9678, 2016, vol. 2016, str. 1-12, ilustr. http://dx.doi.org/10.1155/2016/3585362, doi: 10.1155/2016/3585362. [
15. KOLOŠA, Katja, MOTALN, Helena, HEROLD-MENDE, Christel, KORŠIČ, Marjan, LAH TURNŠEK, Tamara. Paracrine effects of mesenchymal stem cells induce senescence and differentiation of glioblastoma stem-like cells. Cell transplantation, ISSN 0963-6897. [Print ed.], 2015, vol. 24, no. 4, str. 631-644, doi: 10.3727/096368915X687787.
16. 1HIRA, Vashendriya V. V., PLOEGMAKERS, Kimberley J., GREVERS, Frederieke, VERBOVŠEK, Urška, SILVESTRE- ROIG, Carlos, ARONICA, Eleonora, TIGCHELAAR, Wikky, LAH TURNŠEK, Tamara, MOLENAAR, Remco J., NOORDEN, Cornelis J. F. van. CD133+ and nestin+ glioma stem-like cells reside around CD31+ arterioles in niches that express SDF-1[alpha], CXCR4, osteopontin and cathepsin K. The Journal of histochemistry and cytochemistry, ISSN 0022-1554, 2015, vol. 63, no. 7, str. 481-493. http://dx.doi.org/10.1369/0022155415581689, doi: 10.1369/0022155415581689.
17. MOTALN, Helena, KOREN, Ana, GRUDEN, Kristina, RAMŠAK, Živa, SCHICHOR, Christian, LAH TURNŠEK, Tamara. Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance. Oncotarget, ISSN 1949-2553, 2015, vol. 6, no. 38, str. 40998-41017, ilustr., doi: 10.18632/oncotarget.5701.
18. HERMAN, Ana, GRUDEN, Kristina, BLEJEC, Andrej, PODPEČAN, Vid, MOTALN, Helena, ROŽMAN, Primož, HREN, Matjaž, ZUPANČIČ, Klemen, VEBER, Matija, VERBOVŠEK, Urška, LAH TURNŠEK, Tamara, PORČNIK, Andrej, KORŠIČ, Marjan, KNEŽEVIĆ, Miomir, JERAS, Matjaž. Analysis of glioblastoma patients' plasma revealed the presence of microRNAs with a prognostic impact on survival and those of viral origin. PloS one, ISSN 1932-6203, 2015, vol. 10, iss. 5, str. 1-20, ilustr., doi: 10.1371/journal.pone.0125791. [
19. STROJNIK, Tadej, ŠMIGOC, Tomaž, LAH TURNŠEK, Tamara. Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma. Anticancer research, ISSN 0250-7005, 2014, vol. 34, no. 1, str. 339-347, ilustr.
20. VERBOVŠEK, Urška, MOTALN, Helena, ROTTER, Ana, ATAI, Nadia A., GRUDEN, Kristina, NOORDEN, Cornelis J. F. van, LAH TURNŠEK, Tamara. Expression analysis of all protease genes reveals cathepsin K to be overexpressed in glioblastoma. PloS one, ISSN 1932-6203, 2014, vol. 9, iss. 10, str. 1- 12. http://dx.doi.org/10.1371/journal.pone.0111819, doi: 10.1371/journal.pone.0111819.
21. JOVCHEVSKA, Ivana, ŠAMEC, Neja, KOČEVAR BRITOVŠEK, Nina, CESSELLI, Daniela, PODERGAJS, Neža, LIMBÄCK- STOKIN, Clara, MYERS, Michael P., MUYLDERMANS, Serge, HASSANZADEH GHASSABEH, Gholamreza, MOTALN, Helena, RUARO, Maria Elisabetta, BOURKOULA, Evgenia, LAH TURNŠEK, Tamara, KOMEL, Radovan. TRIM28 and [beta]-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers. PloS one, ISSN 1932-6203, Nov. 2014, vol. 9, iss. 11. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0113688, doi: 10.1371/journal.pone.0113688.
22. TORKAR, Ana, LENARČIČ, Brigita, LAH TURNŠEK, Tamara, DIVE, Vincent, DEVEL, Laurent. Identification of new peptide amides as selective cathepsin L inhibitors : the first step towards selective irreversible inhibitors?. Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X. [Print ed.], 2013, vol. 23, issue 10, str. 2968-2973, doi: 10.1016/j.bmcl.2013.03.041
23. PRIMON, Monika, HUSZTHY, Peter C., MOTALN, Helena, TALASILA, Krishna M., TORKAR, Ana, BJERKVIG, Rolf, LAH TURNŠEK, Tamara. Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids. Experimental cell research, ISSN 0014-4827, 2013, vol. 319, iss. 17, str. 2637-2648, doi: 10.1016/j.yexcr.2013.08.011.
24. MOTALN, Helena, GRUDEN, Kristina, HREN, Matjaž, SCHICHOR, Christian, PRIMON, Monika, ROTTER, Ana, LAH TURNŠEK, Tamara. Human mesenchymal stem cells exploit the immune response mediating chemokines to impact the phenotype of glioblastoma. Cell transplantation, ISSN 0963-6897. [Print ed.], 2012, vol. 21, no. 7, str. 1529-1545. http://dx.doi.org/10.3727/096368912X640547, doi: 10.3727/096368912X640547.
25. TORKAR, Ana, BREGANT, Sarah, DEVEL, Laurent, NOVINEC, Marko, LENARČIČ, Brigita, LAH TURNŠEK, Tamara, DIVE, Vincent. A novel photoaffinity-based probe for selective detection of cathepsin L active form. ChemBioChem : a European journal of chemical biology, ISSN 1439-4227. [Print ed.], 2012, vol. 13, issue 17, str. 2616-2621. http://dx.doi.org/10.1002/cbic.201200389, doi: 10.1002/cbic.201200389.
26. SCHICHOR, Christian, ALBRECHT, Valerie, KORTE, Benjamin, BUCHNER, Alexander, RIESENBERG, Rainer, MYSLIWIETZ, Josef, PARON, Igor, MOTALN, Helena, LAH TURNŠEK, Tamara, JÜRCHOTT, Kathrin, SELBIG, Joachim, TONN, Joerg-Christian. Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro. Experimental neurology, ISSN 0014-4886, 2012, vol. 234, issue 1, str. 208-219. http://dx.doi.org/10.1016/j.expneurol.2011.12.033, doi: 10.1016/j.expneurol.2011.12.033.
27. GOLE, Boris, HUSZTHY, Peter C., POPOVIĆ, Mara, JERUC, Jera, ARDEBILI, Seyed Yousef, BJERKVIG, Rolf, LAH TURNŠEK, Tamara. The regulation of cysteine cathepsins and cystatins in human gliomas. International journal of cancer, ISSN 0020-7136. [Print ed.], 2012, vol. 131, issue 8, str. 1779-1789, doi: 10.1002/ijc.27453.
28. ZAJC, Irena, FILIPIČ, Metka, LAH TURNŠEK, Tamara. Xanthohumol induces different cytotoxicity and apoptotic pathways in malignant and normal astrocytes. Phytotherapy research, ISSN 0951-418X, 2012, vol. 26, issue 11, str. 1709-1713. http://dx.doi.org/10.1002/ptr.4636, doi: 10.1002/ptr.4636.
29. KENIG, Saša, FRANGEŽ, Robert, PUCER, Anja, LAH TURNŠEK, Tamara. Inhibition of cathepsin L lowers the apoptotic threshold of glioblastoma cells by up-regulating p53 and transcription of caspases 3 and 7. Apoptosis, ISSN 1360-8185, 2011, vol. 16, no. 7, str. 671-682, doi: 10.1007/s10495-011-0600-6.
30. CASTINO, Roberta, PUCER, Anja, VENERONI, Roberta, MORANI, Federica, PERACCHIO, Claudia, LAH TURNŠEK, Tamara, ISIDORO, Ciro. Resveratrol reduces the invasive growth and promotes the acquisition of a long-lasting differentiated phenotype in human glioblastoma cells. Journal of agricultural and food chemistry, ISSN 0021- 8561, 2011, vol. 59, no. 8, str. 4264-4272. http://dx.doi.org/10.1021/jf104917q, doi: 10.1021/jf104917q.
31. PUCER, Anja, CASTINO, Roberta (adapter), MIRKOVIĆ, Bojana, FALNOGA, Ingrid, ŠLEJKOVEC, Zdenka, ISIDORO, Ciro, LAH TURNŠEK, Tamara. Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells. Biological chemistry, ISSN 1431-6730, 2010, vol. 391, no. 5, str. 519-531. http://dx.doi.org/10.1515/BC.2010.050, doi: 10.1515/BC.2010.050.